Sign In
Last checked at 
5 Apr 2019 08:29
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to members of its senior management team to acquire a total of 1,330,000 ordinary shares of 1.5p each in the capital of the Company under the Company's Share Option Scheme.
The Options have been granted with an exercise price equal to the close price on the day before grant and vest after a period of three years. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. | Details of the person discharging managerial responsibilities / person closely associated | ||||||||||||||||||||||
a. | Name | David Budd CEO Matthew Fowler CFO Gino Miele R&D Director Gordon Powell Commercial Director Colleen Pythian Director of Quality & Regulation Warren Berry Operations Director
| |||||||||||||||||||||
2. | Reason for the notification | ||||||||||||||||||||||
a. | Position/status | 1. | |||||||||||||||||||||
a. | Initial notification /Amendment | Initial notification | |||||||||||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||||||||||||||
a. | Name | genedrive plc | |||||||||||||||||||||
b. | LEI |
213800ZYODIRZ87Y4K14 | |||||||||||||||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||||||||||||||
a. | Description of the Financial instrument, type of instrument Identification code | Options over ordinary shares of 1.5 pence each | |||||||||||||||||||||
b. | Nature of the transaction | Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017. | |||||||||||||||||||||
c. | Price(s) and volume(s) |
| |||||||||||||||||||||
d. | Aggregated information · Aggregated volume · Price
|
N/A
| |||||||||||||||||||||
e. | Date of the transaction | 2019-April-04; UTC time | |||||||||||||||||||||
f. | Place of the transaction | Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options | |||||||||||||||||||||
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO | |
Matthew Fowler: CFO | |
Peel Hunt LLP | +44 (0)207 418 8900 |
James Steel / Oliver Jackson | |
Stanford Capital Partners Limited | +44 (0) 20 3815 8880 |
Patrick Claridge / John Howes | |
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus / Anna Dunphy |
Follow the stocks
